Literature DB >> 11309314

Viruses as antitumor weapons: defining conditions for tumor remission.

D Wodarz1.   

Abstract

Recent research has indicated that viruses specifically infecting tumor cells could be used as an alternative therapeutic approach in cancer patients. A particular example is the adenovirus ONYX-015, which has entered clinical trials in the context of head and neck cancer. Successful therapy crucially requires an understanding about how viral and host parameters influence tumor load. The interactions between the growing tumor, the replicating virus, and possible immune responses are multifactorial and nonlinear. Hence, a complete understanding of how virus and host characteristics influence the outcome of therapy requires mathematical models. In this study, such mathematical models are presented and analyzed. The study investigates three possible scenarios that could be relevant for therapy: (a) viral cytotoxicity alone kills tumor cells; (b) a virus-specific lytic CTL response contributes to killing of infected tumor cells; (c) the virus elicits immunostimulatory signals within the tumor that promote the development of tumor-specific CTL. The models precisely define conditions required for successful therapy. They identify the parameters that need to be measured and modulated to evaluate and refine the existing therapy regimes.

Entities:  

Mesh:

Year:  2001        PMID: 11309314

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Authors:  Amber Miller; Rebecca Nace; Camilo Ayala-Breton C; Michael Steele; Kent Bailey; Kah Whye Peng; Stephen J Russell
Journal:  Mol Ther       Date:  2015-12-09       Impact factor: 11.454

Review 2.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

3.  Use of oncolytic viruses for the eradication of drug-resistant cancer cells.

Authors:  Dominik Wodarz
Journal:  J R Soc Interface       Date:  2009-02-06       Impact factor: 4.118

4.  Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer.

Authors:  Erin S Haley; Gough G Au; Brian R Carlton; Richard D Barry; Darren R Shafren
Journal:  J Mol Med (Berl)       Date:  2009-01-13       Impact factor: 4.599

5.  Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.

Authors:  James J Bull; Roland R Regoes
Journal:  Proc Biol Sci       Date:  2006-11-07       Impact factor: 5.349

6.  ODE models for oncolytic virus dynamics.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  J Theor Biol       Date:  2010-01-18       Impact factor: 2.691

7.  Chemotherapy in conjoint aging-tumor systems: some simple models for addressing coupled aging-cancer dynamics.

Authors:  Mitra S Feizabadi; Tarynn M Witten
Journal:  Theor Biol Med Model       Date:  2010-06-15       Impact factor: 2.432

8.  Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.

Authors:  D Dingli; C Offord; R Myers; K-W Peng; T W Carr; K Josic; S J Russell; Z Bajzer
Journal:  Cancer Gene Ther       Date:  2009-06-05       Impact factor: 5.987

9.  Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection.

Authors:  Dominik Wodarz; Natalia Komarova
Journal:  PLoS One       Date:  2009-01-30       Impact factor: 3.240

Review 10.  ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Authors:  S Ries; W M Korn
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.